Follow the Parabilis Medicines, Inc. stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are listed on US US, under the supervision of SEC (Form 4). Market capitalisation: €3.6bn. The latest transaction was filed on 15 June 2026 (C). Among the most active insiders: Flynn James E. Every trade is openly available.
9
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
·
0 ops.
Sell Volume
11Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
407,132 sharesVoting Common StockSEC:0001193805-26-000798:7
9 of 9 declarations
About Parabilis Medicines, Inc.
Parabilis Medicines, Inc. is a biotechnology company focused on developing innovative treatments for serious diseases. It is listed on the XNAS market.